GLP-1 agonists are a class of medication that mimic a naturally-occurring hormone in the body that signals feelings of satiety. Semaglutide which is the active drug in Rybelsus/Ozempic and Wegovy, and liraglutide which is the active drug in Saxenda, are medications in this class.
​
The medication works in your gut and brain to help you feel full quicker and for longer. Clinical trials have shown that the drug reduces appetite, resulting in healthier food choices and reduced food intake. Participants also reported fewer food cravings and less desire for dairy, savoury, sweet, and high-fat foods. GLP-1 medications make healthy choices more achievable and have been proven to be highly effective when combined with a balanced diet and lifestyle.

Tirzepatide is a dual GIP/GLP-1 receptor agonist and is the active drug in Mounjaro, a drug that was approved by the MHRA in 2023. The principle mechanism of Mounjaro (tirzepatide) is its activation of both the GIP and GLP-1 receptors. It does this by mimicking the incretin hormones GIP and GLP-1 which play a significant role in insulin secretion, satiety and energy balance. By acting on dual receptors, Mounjaro improves blood sugar levels and enhances the feeling of fullness - key factors in achieving weight loss. Studies show, when used alongside a reduced-calorie diet and increased physical activity, Mounjaro leads to significant reductions in body weight.